Top Premarket Gainers
7:55AM ET 1/04/2022 MT NewswiresAllena Pharmaceuticals (ALNA) shares surged 32% on positive trial data for a treatment candidate for hyperuricemia and gout. NeuroBO Pharmaceuticals (NRBO)...
Quotes Snapshot > NRBO
Neurobo Pharmaceuticals Inc NRBO:NASDAQ
Last Price$0.47NASDAQ Previous Close - Last Trade as of 3:49PM ET 7/01/22
Today's Change-0.01(2.04%)
Bid (Size)$0.41 (10)
Ask (Size)$0.52 (3)
Day Low / High$0.46 - 0.51
Volume39.2 K
Read more news Recent News
NeuroBo Pharmaceuticals Says Panel Recommends Continuing COVID-19 Drug Candidate Trial
9:17AM ET 10/13/2021 MT NewswiresNeuroBo Pharmaceuticals (NRBO) said Wednesday that an independent Data Monitoring Committee recommended the continuation of the company's phase 2/3...
NeuroBo Pharmaceuticals Raises $12.7 Million from Securities Offering
2:08PM ET 10/05/2021 MT NewswiresNeuroBo Pharmaceuticals (NRBO) said Tuesday it has sold about 4.3 million shares at $3.25 each, raising around $12.7 million for working capital, capital...
Top Midday Decliners
1:40PM ET 10/01/2021 MT NewswiresOmeros (OMER) said the US Food and Drug Administration has identified certain deficiencies in a review of its biologics license application for narsoplimab...
View all Commentary and Analysis
NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases
10:47AM ET 11/25/2021 Seeking AlphaCompany Profile
Business DescriptionNeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA. View company web site for more details
| Address | 200 Berkeley Street Boston, Massachusetts 02116 |
| Phone | +1.857.702.9600 |
| Number of Employees | 9 |
| Recent SEC Filing | 06/13/2022 4 |
| President, Chief Executive & Medical Officer | Ben Gil Price |
| Senior Vice President-Operations | Matthew Bardin |
| CFO, Secretary, Treasurer & Director | Richard Kang |
| Senior Vice President | Andrew Bartynski |
Company Highlights
| Price Open | $0.47 |
| Previous Close | $0.48 |
| 52 Week Range | $0.37 - 5.63 |
| Market Capitalization | $12.5 M |
| Shares Outstanding | 26.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/15/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.61 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -140.86% |
Analyst Ratings as of 07/22/2020
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |